Vraylar (cariprazine) costs roughly $1,447 for a 30-day supply at its wholesale list price, making it one of the most expensive atypical antipsychotics on the market. That’s 70% to 80% more per year than generic alternatives like aripiprazole or risperidone. The high price comes down to a combination of patent protection, brand-only status, a growing list of FDA-approved uses, and the way insurers handle coverage.
No Generic Version Is Available Yet
The single biggest reason Vraylar costs so much is that no generic version has reached pharmacy shelves. While the FDA actually approved a generic application from Zydus Pharmaceuticals back in September 2022, multiple patents on cariprazine don’t expire until 2028 and 2029. The key patents run through December 2028 and September 2029, which means AbbVie (the manufacturer, through its Allergan subsidiary) can block generic competitors from selling their versions until those dates pass or a legal settlement allows earlier entry.
Without generic competition, AbbVie faces no pricing pressure from cheaper alternatives carrying the same active ingredient. Once generics do launch, prices typically drop dramatically, often 80% or more within a few years. But for now, Vraylar exists in a window where the drug is approved, widely prescribed, and has no direct generic equivalent.
How Vraylar Compares to Cheaper Alternatives
The price gap between Vraylar and older generic antipsychotics is enormous. Generic aripiprazole (the active ingredient in Abilify) costs between $393 and $463 per year. Generic risperidone runs $349 to $524 per year. Vraylar, by comparison, costs roughly $1,789 annually at Canadian formulary prices and considerably more in the U.S., where the list price exceeds $17,000 per year.
That means a patient switching from generic aripiprazole to Vraylar could see their medication costs jump by $1,300 or more per year, even in markets with some price regulation. In the U.S., without insurance, the difference is far steeper.
A Broader Label Justifies Premium Pricing
Vraylar was first approved by the FDA in 2015 for schizophrenia and manic episodes in bipolar I disorder. Since then, AbbVie has expanded its approved uses to include bipolar depression and, more recently, as an add-on treatment for major depressive disorder (MDD) in adults. Each new indication widens the pool of potential patients and gives AbbVie more reason to maintain a high price point.
The MDD indication is particularly significant because depression is far more common than schizophrenia or bipolar disorder. Adding tens of millions of potential patients to the drug’s market makes Vraylar a much bigger revenue opportunity, and pharmaceutical companies price accordingly. A drug approved for four conditions has more commercial value than one approved for two, even if the molecule itself hasn’t changed.
AbbVie also markets Vraylar as pharmacologically distinct from older antipsychotics. Cariprazine has unusually strong activity at a specific type of dopamine receptor (the D3 receptor), which is different from most other drugs in its class. Whether that translates into meaningful clinical advantages for every patient is debated, but the “novel mechanism” framing supports premium pricing and helps justify the drug’s position on formularies.
Insurance Often Puts Vraylar on the Highest Tier
Even with insurance, Vraylar tends to be expensive out of pocket. Many plans place it on Tier 5, the specialty drug tier, which carries the highest copays or coinsurance. On a typical plan, that could mean paying 25% to 33% of the drug’s cost rather than a flat copay of $30 or $50.
Insurers also frequently require prior authorization before covering Vraylar. In practice, this means your prescriber needs to document that you’ve already tried and failed on a cheaper generic antipsychotic, like quetiapine, before the plan will approve coverage. For major depressive disorder, the requirements are even stricter: you typically need to show that you’ve failed on at least one additional generic antidepressant beyond whatever you’re currently taking. These hurdles exist specifically because Vraylar is so much more expensive than the alternatives insurers prefer.
Ways to Lower Your Out-of-Pocket Cost
AbbVie runs a patient assistance program called myAbbVie Assist for people who are uninsured or underinsured. Eligibility is income-based: a single person earning $63,840 or less per year qualifies, and the threshold rises with household size (up to $132,000 for a family of four, plus $22,720 for each additional dependent). If you qualify, the program can provide Vraylar at no cost.
For people with commercial insurance, AbbVie also offers a savings card that can reduce copays, though the exact discount varies by plan. These manufacturer programs don’t lower the actual price of the drug. They shift costs around to keep patients filling prescriptions while the list price stays high. If your insurance requires prior authorization, getting that approval squared away first will make the biggest difference in what you actually pay at the pharmacy.
If cost is a barrier and you haven’t tried older generics, it’s worth knowing that drugs like aripiprazole and risperidone treat several of the same conditions at a fraction of the price. Vraylar may work better for some people, but for many, a generic antipsychotic is a reasonable starting point, and it’s what most insurance plans will expect you to try first regardless.